Recent GRI News
- GRI Bio Announces Reverse Stock Split • GlobeNewswire Inc. • 06/14/2024 12:05:00 PM
- GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference • GlobeNewswire Inc. • 06/11/2024 01:00:00 PM
- GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs • GlobeNewswire Inc. • 05/22/2024 01:15:00 PM
- GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE) • GlobeNewswire Inc. • 05/21/2024 12:35:00 PM
- GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) • GlobeNewswire Inc. • 05/20/2024 12:45:00 PM
- GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase • GlobeNewswire Inc. • 05/14/2024 01:05:00 PM
- GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/13/2024 12:00:00 PM
- GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity • GlobeNewswire Inc. • 04/29/2024 12:45:00 PM
- GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar • GlobeNewswire Inc. • 04/25/2024 01:15:00 PM
- GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent • GlobeNewswire Inc. • 04/16/2024 12:35:00 PM
- GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference • GlobeNewswire Inc. • 04/08/2024 12:35:00 PM
- GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/01/2024 11:35:00 AM
- GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators • GlobeNewswire Inc. • 03/14/2024 12:45:00 PM
- GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom • GlobeNewswire Inc. • 03/04/2024 01:30:00 PM
- GRI Bio Announces Pricing of $5.5 Million Public Offering • GlobeNewswire Inc. • 02/02/2024 01:00:00 PM
- GRI Bio Announces Reverse Stock Split • GlobeNewswire Inc. • 01/26/2024 01:05:00 PM
- GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”) • GlobeNewswire Inc. • 12/05/2023 02:05:00 PM
- GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”) • GlobeNewswire Inc. • 11/27/2023 01:35:00 PM
- GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/15/2023 01:05:00 PM
- GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases • GlobeNewswire Inc. • 10/31/2023 12:45:00 PM
- GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference • GlobeNewswire Inc. • 10/19/2023 12:45:00 PM
- GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression • GlobeNewswire Inc. • 10/17/2023 12:35:00 PM
- GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference • GlobeNewswire Inc. • 10/11/2023 01:05:00 PM
- GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions • GlobeNewswire Inc. • 10/05/2023 12:45:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM